Sold as Geref. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Sermorelin Acetate (sold as Geref), first approved Dec 28, 1990, with 0 new uses approved and 0 published complete response letters.
| Dec 28, 1990 | GerefNDA 19863 · New molecular entity | Emd Serono | 5 | Discontinued |
| Sep 26, 1997 | GerefNDA 20443 · New dosage form | Emd Serono Inc | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
